SSR Health LLC is the leader in US prescription brand drug pricing data and analytics.

Our proprietary net price database is recognized as a critical source of industry data by academics, brand manufacturers, trade associations, policymakers and the mainstream media. Accessible through a powerful and fully customizable web-based interface, SSR Health’s US prescription brand pricing data tool gives clients the ability to assess gross and net pricing dynamics at the industry, market segment, manufacturer, and individual product levels, enhancing operational and strategic decision-making.
Contact Us

SSR Health LLC is the leader in US prescription brand drug pricing data and analytics.

Our proprietary net price database is recognized as a critical source of industry data by academics, brand manufacturers, trade associations, policymakers and the mainstream media. Accessible through a powerful and fully customizable web-based interface, SSR Health’s US prescription brand pricing data tool gives clients the ability to assess gross and net pricing dynamics at the industry, market segment, manufacturer, and individual product levels, enhancing operational and strategic decision-making.
Contact Us

IRA Selection Tool
and Analysis

The SSR Health IRA Selection Tool provides all the information an organization needs to understand the direct and indirect impacts of the IRA Drug Price Negotiation Program. Insights include drug-level probabilities of selection for at least the next 3 IPAYS, historical changes in those probabilities of selection, and quarterly updates to incorporate new policies, guidance, and drug-specific events and sales dynamics.

The tool is driven by a proprietary probabilistic prediction framework informed by a range of data sources, including, most importantly, the 100% Part D and Part B spending files directly from CMS. This gold standard drug-level spending history informs a bootstrapped model that is based on a census of Medicare lifecycles and can generate the most precise range of spending projections in the industry.

Critically, the Selection Tool presents drug-level odds of selection, rather than simple point-estimate sales projections or sales ranks. This allows users to identify brands whose selection odds are similar and whose adaptive responses directly impact a brand’s odds. And the multiple-IPAY forecast horizon gives companies ample time to react with longer-term potential solutions (e.g., HEOR).

Interactive tables and visualizations are hosted on our Tableau Online platform, which offers analyses by company, and/or therapeutic area, or enables clients to perform analyses customized to their specific requirements.

US Prescription Brand
Net Pricing Data
and Analysis

SSR Health’s US prescription brand pricing data tool incorporates quarterly gross and estimated net pricing data and trends since 2007– and for every quarter going forward.

The dataset includes gross and net prices for the majority of active US brand name prescription drugs – approximately 1,000 products across more than 100 companies.

Our client-focused Tableau Online platform provides standardized analyses of net pricing trends by industry, company, and therapeutic area, and enables clients to perform analyses customized to their specific requirements.

Among the available data series are WAC-to-net concessions, Medicaid versus non-Medicaid concessions, product roll-up to industry, therapeutic area and company levels, and both WAC and net prices by year or course of therapy, enabling in-depth comparisons across products and segments.

Drawing on our proprietary dataset and the expertise of our principals, SSR Health provides analysis on drug pricing trends across the industry, together with political and regulatory developments that are impacting – and are projected to impact – products, segments and companies in the space. Among the areas we focus on:

Quarterly pricing trends.

• SSR Health publishes quarterly reports that identify and assess the positive and negative drivers – by company, therapeutic area and product – of aggregate net pricing trends, as well as the factors influencing pharma market dynamics (e.g., co-pay accumulators, formulary exclusions).

US political and regulatory developments.

• We provide objective and actionable analyses of new and proposed legislation and directives (e.g., The Prescription Drug Pricing Reduction Act (PDPRA), International Pricing Index, Anti-Kickback Statute (AKS) safe harbor rule) and their industry impact.

IRA Selection Tool and Analysis

The SSR Health IRA Selection Tool provides all the information an organization needs to understand the direct and indirect impacts of the IRA Drug Price Negotiation Program. Insights include drug-level probabilities of selection for at least the next 3 IPAYS, historical changes in those probabilities of selection, and quarterly updates to incorporate new policies, guidance, and drug-specific events and sales dynamics.

The tool is driven by a proprietary probabilistic prediction framework informed by a range of data sources, including, most importantly, the 100% Part D and Part B spending files directly from CMS. This gold standard drug-level spending history informs a bootstrapped model that is based on a census of Medicare lifecycles and can generate the most precise range of spending projections in the industry.

Critically, the Selection Tool presents drug-level odds of selection, rather than simple point-estimate sales projections or sales ranks. This allows users to identify brands whose selection odds are similar and whose adaptive responses directly impact a brand’s odds. And the multiple-IPAY forecast horizon gives companies ample time to react with longer-term potential solutions (e.g., HEOR).

Interactive tables and visualizations are hosted on our Tableau Online platform, which offers analyses by company, and/or therapeutic area, or enables clients to perform analyses customized to their specific requirements.

US Prescription Brand Net Pricing Data and Analysis

SSR Health’s US prescription brand pricing data tool incorporates quarterly gross and estimated net pricing data and trends since 2007– and for every quarter going forward.

The dataset includes gross and net prices for the majority of active US brand name prescription drugs – approximately 1,000 products across more than 100 companies.

Our client-focused Tableau Online platform provides standardized analyses of net pricing trends by industry, company, and therapeutic area, and enables clients to perform analyses customized to their specific requirements.

Among the available data series are WAC-to-net concessions, Medicaid versus non-Medicaid concessions, product roll-up to industry, therapeutic area and company levels, and both WAC and net prices by year or course of therapy, enabling in-depth comparisons across products and segments.

Drawing on our proprietary dataset and the expertise of our principals, SSR Health provides analysis on drug pricing trends across the industry, together with political and regulatory developments that are impacting – and are projected to impact – products, segments and companies in the space. Among the areas we focus on:

Quarterly pricing trends.

• SSR Health publishes quarterly reports that identify and assess the positive and negative drivers – by company, therapeutic area and product – of aggregate net pricing trends, as well as the factors influencing pharma market dynamics.

US political and regulatory developments.

• We provide objective and actionable analyses of new and proposed legislation and directives - including the Inflation Reduction Act (IRA) - and their industry impact.